Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1984 1
1985 1
1986 1
1987 1
1988 1
1989 2
1990 1
1994 2
1995 2
1996 2
1997 2
1998 2
2001 1
2003 3
2005 2
2006 5
2008 3
2009 1
2010 5
2011 3
2012 4
2013 6
2014 1
2015 2
2016 3
2017 2
2018 3
2019 1
2020 2
2021 4
2022 4
2023 3
2024 5
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Testing growth hormone deficiency in adults.
Gabellieri E, Chiovato L, Lage M, Castro AI, Casanueva FF. Gabellieri E, et al. Front Horm Res. 2010;38:139-144. doi: 10.1159/000318503. Epub 2010 Jul 5. Front Horm Res. 2010. PMID: 20616504 Review.
Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.
Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R; RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Candido R, et al. Nutr Metab Cardiovasc Dis. 2024 Aug;34(8):1846-1853. doi: 10.1016/j.numecd.2024.03.023. Epub 2024 Mar 23. Nutr Metab Cardiovasc Dis. 2024. PMID: 38693036 Free article.
Treatment intensification following glucagon-like peptide-1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE-G real-world study.
Napoli R, Nicolucci A, Larosa M, Rossi MC, Candido R; RESTORE‐G (Retrospective analysis on the therapeutic approaches after GLP‐1 RA treatment in type 2 diabetes patients) Study Group. Napoli R, et al. Diabetes Obes Metab. 2024 Sep;26(9):3576-3586. doi: 10.1111/dom.15697. Epub 2024 Jun 10. Diabetes Obes Metab. 2024. PMID: 38853712
Heat and cold denaturation of yeast frataxin: The effect of pressure.
Puglisi R, Cioni P, Gabellieri E, Presciuttini G, Pastore A, Temussi PA. Puglisi R, et al. Among authors: gabellieri e. Biophys J. 2022 Apr 19;121(8):1502-1511. doi: 10.1016/j.bpj.2022.03.010. Epub 2022 Mar 9. Biophys J. 2022. PMID: 35278425 Free PMC article.
Engineering methionine γ-lyase from Citrobacter freundii for anticancer activity.
Raboni S, Revtovich S, Demitri N, Giabbai B, Storici P, Cocconcelli C, Faggiano S, Rosini E, Pollegioni L, Galati S, Buschini A, Morozova E, Kulikova V, Nikulin A, Gabellieri E, Cioni P, Demidkina T, Mozzarelli A. Raboni S, et al. Among authors: gabellieri e. Biochim Biophys Acta Proteins Proteom. 2018 Dec;1866(12):1260-1270. doi: 10.1016/j.bbapap.2018.09.011. Epub 2018 Sep 27. Biochim Biophys Acta Proteins Proteom. 2018. PMID: 30268810 Free article.
Soluble and Nanoporous Silica Gel-Entrapped C. freundii Methionine γ-Lyase.
Morozova EA, Kulikova VV, Faggiano S, Raboni S, Gabellieri E, Cioni P, Anufrieva NV, Revtovich SV, Demidkina T, Mozzarelli A. Morozova EA, et al. Among authors: gabellieri e. J Nanosci Nanotechnol. 2018 Mar 1;18(3):2210-2219. doi: 10.1166/jnn.2018.14333. J Nanosci Nanotechnol. 2018. PMID: 29448748
SARS-Cov-2 Infection: A New Risk Factor for Pituitary Apoplexy?
Ragni A, Bendotti G, Biamonte E, Cavigiolo B, Gabellieri E, Leporati P, Mollero ELM, Gallo M. Ragni A, et al. Among authors: gabellieri e. Endocr Metab Immune Disord Drug Targets. 2024 Apr 26. doi: 10.2174/0118715303315494240419060719. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 38676521
75 results